ORG Partners LLC Acquires 111 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

ORG Partners LLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 108.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213 shares of the pharmaceutical company’s stock after acquiring an additional 111 shares during the period. ORG Partners LLC’s holdings in Vertex Pharmaceuticals were worth $103,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Mascagni Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $31,000. SJS Investment Consulting Inc. boosted its holdings in Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock worth $46,000 after buying an additional 30 shares during the period. Truvestments Capital LLC boosted its holdings in Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after buying an additional 23 shares during the period. Mpwm Advisory Solutions LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $40,000. Finally, Midwest Capital Advisors LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $41,000. Institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 6th. Wolfe Research downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $535.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $513.14.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $440.87 on Friday. The company has a market capitalization of $113.22 billion, a price-to-earnings ratio of -112.47 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The firm’s 50-day moving average is $459.22 and its 200 day moving average is $459.52. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.76 earnings per share. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.